Treatments are currently under clinical development for Huntington’s disease (licensed to Teva Pharmaceutical Industries) and for solid cancer (licensed to NeoTX Therapeutics). In addition, activities are ongoing to find strategic and competent partners to secure the continued development of tasquinimod for the treatment of multiple myeloma, paquinimod for systemic sclerosis and the pre-clinical projects within the SILC program.
Active Biotech
The project portfolio of Active Biotech comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.
